JonesTrading analyst Soumit Roy has maintained their neutral stance on EDIT stock, giving a Hold rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Soumit Roy’s rating is based on a combination of factors that reflect Editas Medicine’s current strategic position and future prospects. The company is in the process of selecting a developmental candidate for its hematopoietic stem cells or liver program, with plans to submit an IND by mid-2026 and share initial human proof-of-concept data by the end of 2026. This indicates a cautious but forward-looking approach to development, which may not immediately translate into significant stock movement.
Additionally, Editas has a collaboration with Bristol Myers Squibb, which has resulted in milestone payments and a steady cash position, providing a financial cushion. However, the company’s cash burn rate and the need for further capital and resource allocation for future developments pose potential risks. These factors, combined with the company’s current cash runway into the second quarter of 2027, suggest a balanced outlook, leading to the Hold rating.
Roy covers the Healthcare sector, focusing on stocks such as Enliven Therapeutics, Nuvation Bio, and Precision BioSciences. According to TipRanks, Roy has an average return of -22.3% and a 20.56% success rate on recommended stocks.